Table 1 Patient characteristics

Male/Female sex, n (%)

27 (59)/19 (41)

32 (65)/14 (35)

23 (70)/10 (30)

Spinal/Bulbar onset, n (%)

36 (78)/10 (22)

35 (71)/14 (29)

26 (79)/7 (21)

Age at disease onset, mean (SD), years

60.1 (11.3)

61.9 (10.4)

49.5 (11.7)

Age at baseline, mean (SD), years

61.3 (11.6)

63.4 (10.2)

51.3 (11.7)

Disease duration at baseline, median (IQR), months

10.1 (6.51–19.4)

14.8 (9.4–28.4)

20 (13.0–29.5)

ALSFRS-R Score at baseline, median (IQR), points

42 (39.8–44.0)

37 (30.5–42.0)

39 (34.0–43.0)

ΔFRS, median (IQR), -pt/m

0.56 (0.26–0.98)

0.60 (0.34–1.15)

0.44 (0.28–0.76)

BMI at baseline, median (IQR), kg/m²

25.4 (24.1–28.8)

24.0 (22.6–26.7)

23.8 (22.4–26.6)

Follow-up time, median (IQR), months

13.1 (6.8–19.5)

13.0 (9.0–18.0)

18.0 (18.0–18.0)

ALSFRS-R slope in entire follow-up, median (IQR), -pt/m

0.73 (0.34–1.16)

1.02 (0.48–1.55)

0.61 (0.32–0.86)

ALSFRS-R slope in interventional period, median (IQR), -pt/m

0.83 (0.49–1.49); n = 40

0.50 (0.25–0.87); n = 33

Baseline NfL levels, median (IQR), pg/ml

115 (64–174)

94 (54–141)

54 (33–86)

Baseline ln(NfL) levels, mean (SD), pg/ml

4.63 (0.81)

4.58 (0.83)

3.95 (0.66)